60 Degrees’ Arakoda Gets US FDA Panel Nod For Malaria Prophylaxis
Executive Summary
Postmarketing studies are needed to assess tafenoquine’s efficacy in children, older adults and heavier individuals, and to answer questions about psychiatric safety and other adverse events, advisory committee says.
You may also be interested in...
Finance Watch: Apogee, Sagimet Launch First Big US IPOs Of The Summer
Public Company Edition: Apogee grossed $300m and Sagimet raised $85m in the biggest initial public offerings in the US since Acelyrin’s $540m IPO in May. Also, Bausch entered into a $600m funding facility with KKR, Bicycle raised $200m in a FOPO and Caribou garnered $150m from an offering and Pfizer.
What’s Next? Five Things To Look Out For In July
Generics Bulletin previews the most notable and anticipated events for July 2023.
Keeping Track: Poteligeo, Onpattro, Galafold And Annovera Approved; Selinexor Submitted
The latest drug development news and highlights from our US FDA Performance Tracker.